Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2006

View Archived Issues

YM-201627 presented as a new agent for solid tumors

Preclinical experiments support use of desvenlafaxine for menopause symptoms

Increlex stability, structural features detailed

GTx reports on novel nonsteroidal selective androgen receptor modulators

Cardioprotective effects of a new exendin-4 analogue

Iplex shows promise in severe insulin resistance syndromes

Bremelanotide affects desire and arousal in female sexual arousal disorder patients

S-2367 shows efficacy in maintaining and continuing weight loss in obese subjects

Japanese submission for minodronic acid hydrate in osteoporosis

Pivotal study begins for HuMax-CD20 in NHL

Takeda licenses rights to Galaxy's anti-HGF antibody

Grant for study of alagebrium effects on renal function in diabetes patients

Antigenics and GSK expand license and supply agreements for QS-21 adjuvant

Approvable letter for Cellegesic

Pivotal study of Mozobil completes enrollment

PRX-08066 relaxes pulmonary arteries without affecting systemic blood pressure in rodents

Astemizole shows antimalarial potential in preclinical studies

JNJ-1250132: A unique progesterone receptor modulator

Hemopure submitted for U.K. approval

Avandamet approved for initial treatment of type 2 diabetes

FDA approves Emend for prevention of postoperative nausea and vomiting

Recent patents report novel vanilloid VR1 receptor antagonists

Recent patents disclose novel agents for HCV infection

Schizophrenia, depression, etc. targets of newly patented compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...